{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T20:15:35Z","timestamp":1780431335652,"version":"3.54.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.exphem.2025.105250","type":"journal-article","created":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T14:18:52Z","timestamp":1757859532000},"page":"105250","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["An engineered IgM antibody targeting CD20 has enhanced complement-dependent cytotoxicity compared with an IgG"],"prefix":"10.1016","volume":"152","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8113-9212","authenticated-orcid":false,"given":"Kevin C.","family":"Hart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9554-4144","authenticated-orcid":false,"given":"Paul R.","family":"Hinton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marigold","family":"Manlusoc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin B.","family":"Carlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5792-4015","authenticated-orcid":false,"given":"Samuel","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya F.","family":"Kotturi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9879-9238","authenticated-orcid":false,"given":"Ramesh","family":"Baliga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3508-9223","authenticated-orcid":false,"given":"Bruce A.","family":"Keyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2025.105250_bib0001","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2019.1690959","article-title":"Regulation of antibody-mediated complement-dependent cytotoxicity by modulating the intrinsic affinity and binding valency of IgG for target antigen","volume":"12","author":"Wang","year":"2020","journal-title":"MAbs"},{"key":"10.1016\/j.exphem.2025.105250_bib0002","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.1021\/acs.nanolett.9b02220","article-title":"Unraveling the macromolecular pathways of IgG oligomerization and complement activation on antigenic surfaces","volume":"19","author":"Strasser","year":"2019","journal-title":"Nano Lett"},{"key":"10.1016\/j.exphem.2025.105250_bib0003","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.1248943","article-title":"Complement is activated by IgG hexamers assembled at the cell surface","volume":"343","author":"Diebolder","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.exphem.2025.105250_bib0004","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.molcel.2016.05.016","article-title":"Molecular basis of assembly and activation of complement component C1 in complex with immunoglobulin G1 and antigen","volume":"63","author":"Wang","year":"2016","journal-title":"Mol Cell"},{"key":"10.1016\/j.exphem.2025.105250_bib0005","first-page":"619","article-title":"Rituximab in the treatment of non-Hodgkin\u2019s lymphoma","volume":"2","author":"Hauptrock","year":"2008","journal-title":"Biologics"},{"key":"10.1016\/j.exphem.2025.105250_bib0006","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1634\/theoncologist.2017-0150","article-title":"The role of rituximab in chronic lymphocytic leukemia treatment and the potential utility of biosimilars","volume":"23","author":"Brown","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.exphem.2025.105250_bib0007","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2025.105250_bib0008","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ctrv.2012.10.008","article-title":"Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies","volume":"39","author":"Okroj","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.exphem.2025.105250_bib0009","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1126\/science.aaz9356","article-title":"Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab","volume":"367","author":"Rouge","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.exphem.2025.105250_bib0010","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.0902-4441.2003.00196.x","article-title":"Monoclonal antibodies in the treatment of autoimmune cytopenias","volume":"72","author":"Robak","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.exphem.2025.105250_bib0011","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/10428190902878471","article-title":"Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention","volume":"50","author":"Stolz","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2025.105250_bib0012","first-page":"392","article-title":"Haemolytic complement in peripheral lymph of normal men","volume":"32","author":"Olszewski","year":"1978","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.exphem.2025.105250_bib0013","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/ard.2008.092791","article-title":"Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation","volume":"68","author":"Teng","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.exphem.2025.105250_bib0014","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/rheumatology\/key428","article-title":"Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis","volume":"58","author":"Ramwadhdoebe","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.exphem.2025.105250_bib0015","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.autrev.2006.09.008","article-title":"The role of complement regulatory proteins (CD55 and CD59) in the pathogenesis of autoimmune hemocytopenias","volume":"6","author":"Ruiz-Arg\u00fcelles","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.exphem.2025.105250_bib0016","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.4049\/jimmunol.1600648","article-title":"Antibodies that efficiently form hexamers upon antigen binding can induce complement-dependent cytotoxicity under complement-limiting conditions","volume":"197","author":"Cook","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2025.105250_bib0017","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.molimm.2015.12.007","article-title":"Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells","volume":"70","author":"Lindorfer","year":"2016","journal-title":"Mol Immunol"},{"key":"10.1016\/j.exphem.2025.105250_bib0018","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0161-5890(01)00025-6","article-title":"Role of natural and immune IgM antibodies in immune responses","volume":"37","author":"Boes","year":"2000","journal-title":"Mol Immunol"},{"key":"10.1016\/j.exphem.2025.105250_bib0019","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/08916930500124452","article-title":"IgM is required for efficient complement mediated phagocytosis of apoptotic cells in vivo","volume":"38","author":"Ogden","year":"2005","journal-title":"Autoimmunity"},{"key":"10.1016\/j.exphem.2025.105250_bib0020","doi-asserted-by":"crossref","first-page":"6031","DOI":"10.4049\/jimmunol.0804191","article-title":"IgM antibodies to apoptosis-associated determinants recruit C1q and enhance dendritic cell phagocytosis of apoptotic cells","volume":"182","author":"Chen","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2025.105250_bib0021","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/antib9040053","article-title":"Structure, function, and Therapeutic Use of IgM Antibodies","volume":"9","author":"Keyt","year":"2020","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.exphem.2025.105250_bib0022","doi-asserted-by":"crossref","first-page":"13093","DOI":"10.1021\/bi801131h","article-title":"Interaction of human C1q with IgG and IgM: revisited","volume":"47","author":"Gadjeva","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.exphem.2025.105250_bib0023","doi-asserted-by":"crossref","first-page":"11900","DOI":"10.1073\/pnas.1901841116","article-title":"Insights into IgM-mediated complement activation based on in situ structures of IgM-C1-C4b","volume":"116","author":"Sharp","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2025.105250_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066739","article-title":"Real time assays for quantifying cytotoxicity with single cell resolution","volume":"8","author":"Hsiao","year":"2013","journal-title":"PLOS One"},{"key":"10.1016\/j.exphem.2025.105250_bib0025","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1158\/1078-0432.CCR-08-1536","article-title":"An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy","volume":"15","author":"Mishima","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2025.105250_bib0026","article-title":"Systematic quantification of population cell death kinetics in mammalian cells","volume":"4","author":"Forcina","year":"2017","journal-title":"Cell Syst"},{"key":"10.1016\/j.exphem.2025.105250_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107845","article-title":"Kinetic heterogeneity of cancer cell fractional killing","volume":"32","author":"Inde","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.exphem.2025.105250_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2021.100300","article-title":"Quantification of drug-induced fractional killing using high-throughput microscopy","volume":"2","author":"Inde","year":"2021","journal-title":"STAR Protoc"},{"key":"10.1016\/j.exphem.2025.105250_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/0167-5699(89)90244-2","article-title":"IgM\u2014molecular requirements for its assembly and function","volume":"10","author":"Davis","year":"1989","journal-title":"Immunol Today"},{"key":"10.1016\/j.exphem.2025.105250_bib0030","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.leukres.2005.09.008","article-title":"Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines","volume":"30","author":"Takei","year":"2006","journal-title":"Leuk Res"},{"issue":"1 Suppl 2","key":"10.1016\/j.exphem.2025.105250_bib0031","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/sonc.2002.30156","article-title":"Rituximab: mechanism of action and resistance","volume":"29","author":"Maloney","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.exphem.2025.105250_bib0032","doi-asserted-by":"crossref","first-page":"eabn7824","DOI":"10.1126\/scitranslmed.abn7824","article-title":"An ex vivo platform to guide drug combination treatment in relapsed\/refractory lymphoma","volume":"14","author":"Goh","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.exphem.2025.105250_bib0033","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.clim.2017.05.016","article-title":"Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9","volume":"181","author":"Taylor","year":"2017","journal-title":"Clin Immunol"},{"key":"10.1016\/j.exphem.2025.105250_bib0034","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3390\/cancers17050907","article-title":"Molecular mechanisms in the transformation from indolent to aggressive B cell malignancies","volume":"17","author":"Maher","year":"2025","journal-title":"Cancers (Basel)"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X25005399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X25005399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T21:42:13Z","timestamp":1763674933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X25005399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":34,"alternative-id":["S0301472X25005399"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2025.105250","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An engineered IgM antibody targeting CD20 has enhanced complement-dependent cytotoxicity compared with an IgG","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2025.105250","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Experimental Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105250"}}